Metastatic Melanoma is a Challenging Malignancy to Treat Historically.

Until 2011, only dacarbazine and high-dose interleukin 2 (IL-2) were approved for the treatment of metastatic disease. These therapies are not active in melanoma and with the advances in immunotherapy and targeted treatment, chemotherapy is not used as frequently.